Results 31 to 40 of about 3,132 (216)

TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

Ophthalmology (Rochester, Minn.)
PURPOSE To evaluate the 2-year efficacy, durability, and safety of the bispecific antibody, faricimab, which inhibits both angiopoietin-2 and vascular endothelial growth factor-A.
Arshad M. Khanani, A. Kotecha, Andrew Chang, Shih-Jen Chen, You-Xin Chen, Robyn Guymer, Jeff Heier, F. Holz, Tomohiro Iida, Jane A. Ives, Jennifer I. Lim, Hugh Lin, Stephan Michels, Carlos Quezada Ruiz, Ursula Schmidt-Erfurth, David Silverman, Rishi P. Singh, Balakumar Swaminathan, Jeffrey R. Willis, R. Tadayoni   +19 more
semanticscholar   +1 more source

Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study

Clinical Ophthalmology
Purpose To evaluate the efficacy of faricimab in real-world clinical settings in India for treating diabetic macular edema (DME) in treatment-naïve and recalcitrant eyes.
Debdulal Chakraborty, Sudipta Das, Aniruddha Maiti, T. Sinha, A. Das, J. Sheth, S. Boral, S. Mondal, K. Nandi   +8 more
semanticscholar   +1 more source

Faricimab for treating diabetic macular oedema

, 2021
To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating diabetic macular ...
Frampton, Geoff, Scott, David Alexander, Kalita, Neelam, Maund, Emma, Cooper, Keith, Pickett, Karen, Takahashi, Marcia Tomie   +6 more
core   +1 more source

Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review

Ophthalmology Science
Purpose Since faricimab (Vabysmo) was approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), a growing body of real-world data has been reported, forming an important source of evidence for ...
Varun Chaudhary, R. Guymer, A. Artignan, Amanda Downey, Rishi P. Singh   +4 more
semanticscholar   +1 more source

Dynamics of Treatment Response to Faricimab for Diabetic Macular Edema [PDF]

This study analyzes the dynamics of short-term treatment response to the first intravitreal faricimab injection in eyes with diabetic macular edema (DME). This retrospective, single-center, clinical trial was conducted at the Department of Ophthalmology,
Rejdak, M, Cozzi, M, Mariano Cozzi, Kvanta, A,, Blaser, F, Katrin Fasler, Daniel R. Muth, Muth, DR, Anders Kvanta, Zweifel, SA, Fasler, K, Sandrine Zweifel, Daniel Rudolf Muth, Magdalena Rejdak, Sandrine A. Zweifel, Frank Blaser   +15 more
core   +3 more sources

Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis

Pharmacological Research
Background: Faricimab stands as the inaugural and sole bispecific antibody approved by the US Food and Drug Administration (FDA) for intravitreal injection. Nonetheless, the efficacy and safety of intravitreal faricimab remained uncertain.
Guanran Zhang, Xin Wen, Yanrong Li, Junran Sun, Huixun Jia, Xiaodong Sun   +5 more
doaj   +1 more source

Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation

Ophthalmology and Therapy
Introduction To assess the efficacy, durability, and safety of faricimab compared with aflibercept over 1 year in patients with diabetic macular edema (DME) from the China RHINE subpopulation.
Xiaorong Li, Xiaoling Liu, Qin Jiang, Zhifeng Wu, Mei Han, Qiuyu Chen, Oluwatobi O. Idowu, Ruyuan Liu, Wenxin Liu, Jeffrey R. Willis, Xiaodong Sun   +10 more
doaj   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Evaluating the Real-World Efficacy and Safety of Intravitreal Faricimab in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review

IJRETINA (International Journal of Retina)
Introduction: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in the elderly. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the treatment of nAMD ...
Dany Petra Pranata Barus, Gitalisa Andayani Adriono   +1 more
doaj   +1 more source